<DOC>
	<DOCNO>NCT00446446</DOCNO>
	<brief_summary>To estimate effect second-line panitumumab monotherapy objective response patient metastatic recurrent squamous cell carcinoma head neck ( SCCHN ) .</brief_summary>
	<brief_title>PRISM ( Panitumumab Regimen In Second-line Monotherapy Head Neck Cancer )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm squamous cell carcinoma head neck ( SCCHN ) oropharynx , oral cavity , hypopharynx , larynx least 1 measurable lesion use compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan Diagnosis recurrent disease determine incurable surgery radiotherapy Karnofsky Performance Status ( KPS ) score ≥ 60 % screen Men woman age ≥18 year Adequate hematologic , electrolyte hepatic function negative pregnancy test Subject receive &gt; 1 chemotherapy regimen treatment metastatic recurrent disease Concomitant chemotherapy recurrent disease administer solely purpose radiation sensitization reirradiation count towards chemotherapy regimen Nasopharyngeal carcinoma , salivary gland primary skin SCCHN , symptomatic central nervous system ( CNS ) metastases History interstitial lung disease , significant cardiovascular disease , another primary cancer Known positive test human immunodeficiency virus ( HIV ) infection , hepatitis C virus , acute chronic hepatitis B infection Known allergy hypersensitivity component panitumumab Prior antiepidermal growth factor receptor ( EGFr ) antibody therapy ( eg , panitumumab , cetuximab ) treatment small molecule EGFr inhibitor ( eg , gefitinib , erlotinib , lapatinib ) recurrent metastatic disease follow exception : Prior EGFr inhibitor therapy allow received part prior multimodality treatment ( eg , radiation sensitizer ) complete &gt; 24 week prior randomization Subjects receive one dose cetuximab discontinue prior progression due document severe infusion reaction eligible . Significant thromboembolic event ≤ 8 week prior enrollment Subjects recover previous acute radiotherapyrelated toxicity History severe skin disorder opinion investigator may interfere study conduct History medical , psychiatric condition , laboratory abnormality may interfere interpretation study result Subject currently clinical trial ≤ 30 day prior enrollment Subjects require use immunosuppressive agent however corticosteroid allow Man woman childbearing potential consent use adequate contraceptive precaution course study Female subject pregnant breastfeeding Subject require major surgery use general/spinal anesthesia ≤ 28 day prior enrollment , minor surgery ≤ 14 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>